|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2000-7-18
|
|
pubmed:abstractText |
To investigate dose escalation of oral paclitaxel in combination with dose increment and scheduling of cyclosporine (CsA) to improve the systemic exposure to paclitaxel and to explore the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:BeijnenJ HJH,
pubmed-author:DuchinKK,
pubmed-author:HuininkW WWW,
pubmed-author:KoopmanF JFJ,
pubmed-author:LieverstJJ,
pubmed-author:MalingréM MMM,
pubmed-author:RosingHH,
pubmed-author:SchellensJ HJH,
pubmed-author:SwartMM,
pubmed-author:TerwogtJ MJM,
pubmed-author:van TellingenOO
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2468-75
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10856107-Administration, Oral,
pubmed-meshheading:10856107-Adult,
pubmed-meshheading:10856107-Aged,
pubmed-meshheading:10856107-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10856107-Area Under Curve,
pubmed-meshheading:10856107-Cyclosporine,
pubmed-meshheading:10856107-Dose-Response Relationship, Drug,
pubmed-meshheading:10856107-Drug Interactions,
pubmed-meshheading:10856107-Enzyme Inhibitors,
pubmed-meshheading:10856107-Female,
pubmed-meshheading:10856107-Humans,
pubmed-meshheading:10856107-Male,
pubmed-meshheading:10856107-Middle Aged,
pubmed-meshheading:10856107-Neoplasms,
pubmed-meshheading:10856107-Paclitaxel
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of oral paclitaxel.
|
|
pubmed:affiliation |
Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Utrecht, The Netherlands. apmmg@slz.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
